LaSalud.mx .- In addition to the coronavirus, another viral disease that can cause death is influenza, because if it is not treated in time it can cause serious health problems. Fortunately, the vaccine for this virus is available every year to prevent the variants from affecting the immunization of the population.
The use of any vaccine seeks stimulate the recognition of the immune system to the virus component in question, so that, when the body becomes infected, it allows the immune system a faster and more efficient response to defend itself against the virus.
According to the doctor Arturo Galindo Fraga, specialist in infectology, “currently in Mexico only inactivated virus vaccines are used, which allow antigenic recognition and the production of neutralizing antibodies against the virus. “
The influenza virus is composed of RNA genetic material and has the characteristic of presenting a high frequency of changes in its genome, known as drifts, which can cause the virus to evade neutralization by antibodies obtained with the vaccine.
“These changes are what make it necessary to annually review the virus strains that are included in the composition of the vaccine, seeking that they coincide as closely as possible with the circulating strains to maximize the protection effect of the vaccination.”, Indicated the specialist.
Therefore, every year, the Health Secretary calls on the population to go and get vaccinated against the virus and remain alert to symptoms, which include very high fever, muscle aches, dry cough, sore throat, among others. In addition, it must be borne in mind that, even when vaccinated, there is still the risk of contagion.
Fortunately, today there are antiviral treatments that help counteract the disease. According to Dr. Galindo, at the moment there are three pharmacological groups in clinical use that had or are effective against influenza.
These groups are the Adamantanos, which lost effectiveness due to circulating strains. The Selective endonuclease inhibitors, which are effective against influenza A and B. The Ineurominidase inhibitors, in our country, the drug available in this group is the Oseltamivir, which acts on the main protein of the virus and blocks its replication capacity in the body.
Although there are mutations that generate resistance to Oseltamivir, the frequency of its presentation in circulating strains is less than 1%. This medicine must be prescribed by a specialist to ensure its correct use. In Mexico, the only laboratory that has it is Liomon.
Although science has managed to counteract the mortality of the virus, it is essential follow the prevention recommendations indicated by the authorities during this season.